
    
      This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single
      and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to
      assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5718 in healthy
      male subjects
    
  